Welcome to our dedicated page for Theralase Technologies news (Ticker: TLTFF), a resource for investors and traders seeking the latest updates and insights on Theralase Technologies stock.
Theralase Technologies Inc. (TLTFF) is a clinical stage pharmaceutical company whose news flow centers on the development of light, radiation, sound and drug-activated small molecule compounds for the destruction of cancers, bacteria and viruses. Company announcements frequently highlight progress in its oncology and antiviral programs, financing activities and collaborations with partners.
Investors following TLTFF news can expect regular updates on Theralase’s Phase II clinical study in Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer carcinoma in situ, where the company is clinically investigating light-activated Ruvidar. Releases have included interim clinical response data, enrollment status and timelines for data lock and regulatory submissions as described by the company.
News items also cover preclinical research, such as studies of radiation-activated Rutherrin in multiple cancer models and peer-reviewed data on Ruvidar as an antiviral candidate against Herpes Simplex Virus Type 1. These updates summarize scientific findings, mechanisms under investigation and potential implications for future development, as presented by Theralase and collaborating researchers.
From a capital markets perspective, Theralase’s news includes details of non-brokered private placements, warrant extensions and short-term loans, along with the intended use of proceeds for clinical studies, development work and working capital. The company also issues reminders and summaries for investor conference calls where management discusses financial statements and operational milestones.
This TLTFF news page aggregates these disclosures so readers can review company-stated clinical, scientific and financing developments in one place and monitor how Theralase describes the evolution of its small molecule programs over time.
Theralase (OTCQB: TLTFF) reported preclinical data (March 9, 2026) showing X-Ray-activated Rutherrin significantly increased destruction of muscle invasive bladder cancer (MIBC) versus radiation alone. In mice, tumour sites had ~4x Rutherrin uptake; Rutherrin + radiation produced complete tumour clearance at day 35 versus persistent disease or humane endpoints with radiation alone.
The company plans a Phase 0/I/II adaptive clinical study of radiation-activated Rutherrin for MIBC, subject to regulatory approval.
Theralase (OTCQB: TLTFF) reported in vitro data showing that combining light-activated Ruvidar with recombinant human interferon alpha-2b produced substantially greater bladder cancer cell kill than interferon alone. Key finding: the combination yielded 50–65% higher total cell kill versus no Ruvidar across tested doses.
The results showed dose-dependent cytotoxicity for both agents and support a planned combinational clinical study for BCG-unresponsive NMIBC CIS patients.
Theralase (OTCQB: TLTFF) announced interim Phase II bladder cancer data will be presented at the 2026 European Association of Urology Congress (EAU26) in London, March 13-16, 2026. Enrollment in the BCG-unresponsive NMIBC CIS Study II is complete.
Results show early signals: 2 of 3 patients achieved complete response, 2 of 5 maintained response ≥15 months, and 1 of 5 showed ≥3 years duration after a single treatment. The company plans rolling regulatory submissions to Health Canada and the FDA beginning 3Q2026, with approval targeted in 2027.
Theralase (OTCQB: TLTFF) announced interim Phase II clinical data for light-activated Ruvidar (TLD-1433) in BCG-unresponsive non-muscle invasive bladder cancer carcinoma in-situ (NMIBC CIS), selected for oral presentation at EAU26 in London, March 13–16, 2026.
Enrollment in the international, multicenter Study II is complete. Interim findings show 2 of 3 patients achieved complete response, 2 of 5 maintained response ≥15 months, and 1 of 5 showed ≥3 years' response after one treatment. A rolling submission to Health Canada and FDA is planned to start in 3Q2026, with regulatory approval expected in 2027.
Theralase (OTCQB: TLTFF) announced interim Phase II clinical data for light-activated Ruvidar (TLD-1433) in BCG-unresponsive non-muscle invasive bladder cancer carcinoma in-situ (NMIBC CIS), accepted for interactive poster presentation at the 2026 AUA Annual Meeting (May 15-18, 2026).
The interim dataset highlights 78 patients who completed enrollment, with select responses: 2/3 complete responses in a subset, 2/5 maintaining response ≥15 months, and 1/5 showing ≥3-year duration after a single treatment. Rolling regulatory submissions to Health Canada and the FDA are expected to begin in 3Q2026, with approvals targeted in 2027.
Theralase (OTCQB: TLTFF) reported interim Phase II bladder cancer results, enrolling 90 patients with 78 completions and 12 pending. Primary endpoint: CR 64.4% (56/87), total response 73.6% at any time. Duration analysis (450 days) shows CR 40.4% (19/47). Safety: 100% (78/78) evaluated as unrelated or unlikely related to study drug/device. Company plans 2026 data compilation for submissions to Health Canada and FDA with targeted regulatory approval in 2027.
Theralase (TSXV: TLT) (OTCQB: TLTFF) completed enrollment and treatment of 90 patients in a multi-center Phase II registrational study for BCG-unresponsive NMIBC CIS using light-activated Ruvidar.
The study’s primary endpoint is efficacy; secondary is duration of response and tertiary is safety. Company expects study completion and preparation of Health Canada and FDA submissions in 2026.
Ferring Pharmaceuticals and Theralase (TSXV: TLT / OTCQB: TLTFF) announced a clinical development agreement dated January 9, 2026 to evaluate combination therapy in BCG-unresponsive non‑muscle invasive bladder cancer (NMIBC) CIS ± Ta/T1.
The study will add a new cohort to Theralase's Study II (NCT03945162) to test light‑activated Ruvidar (TLD‑1433) followed by Ferring's FDA‑approved intravesical gene therapy ADSTILADRIN (nadofaragene firadenovec‑vncg). Theralase remains sponsor; enrollment will begin in the U.S. with possible expansion pending written agreement. Study II has enrolled 88 of 90 patients with enrollment expected complete by 1Q2026 and follow‑up by 2Q2027.
Theralase (OTCQB: TLTFF) closed a non-brokered private placement on Dec 23, 2025, issuing 7,850,882 Units at CAN$0.17 per Unit for gross proceeds of approximately CAN$1,334,650. Each Unit includes one common share and one warrant exercisable at CAN$0.21 for 5 years. Proceeds will fund the ongoing Phase II Non-Muscle Invasive Bladder Cancer (NMIBC) clinical study, working capital and general corporate purposes.
The company paid a finder's fee totalling CAN$31,658 (CAN$15,470 cash and CAN$16,188 in 95,221 common shares) and issued 186,221 non-transferable finder warrants exercisable at CAN$0.21 for 5 years. Securities are subject to a four-month plus one day hold expiring April 24, 2026, and the Offering awaits TSX Venture Exchange final acceptance.
Theralase (OTCQB: TLTFF, TSXV: TLT) commenced a non-brokered private placement to raise up to CAD 2,000,000 by issuing Units at CAD 0.17 each. Each Unit includes one common share and one warrant exercisable at CAD 0.21 for 60 months. Proceeds are earmarked to fund the ongoing Phase II NMIBC clinical study and working capital. Closing is expected the week of December 15, 2025, subject to TSXV approval. Finder compensation: 7% cash of gross proceeds plus non-transferable finder warrants equal to 7% of Units, exercisable at CAD 0.17 for 60 months. The company also mutually terminated the previously announced LIFE financing with Research Capital.